
    
      The patient population will be molecularly defined and include IDH1R132H mutant grade III and
      IV gliomas without co-deletion of 1p/19q and with loss of alpha-thalassemia/mental
      retardation syndrome X-linked (ATRX) expression.

      Within this trial, the IDH1 peptide vaccine will be administered to 39 patients.

      In treatment group 1 vaccination treatment will be done alone starting 4-6 weeks post
      radiotherapy. In treatment groups 2 and 3 vaccination treatment will be done in parallel with
      temozolomide (TMZ) chemotherapy starting at day 10 of the 4th TMZ cycle (treatment group 2)
      or at day 10 of the 1st TMZ cycle post concomitant radiochemotherapy (treatment group 3).
    
  